219 related articles for article (PubMed ID: 32124692)
41. Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel Disease.
Pashazadeh P; Marjani A; Asadi J; Khoshnia M
Endocr Metab Immune Disord Drug Targets; 2019; 19(4):541-547. PubMed ID: 30451123
[TBL] [Abstract][Full Text] [Related]
42. Pharmacogenetics in acute lymphoblastic leukemia.
Cheok MH; Pottier N; Kager L; Evans WE
Semin Hematol; 2009 Jan; 46(1):39-51. PubMed ID: 19100367
[TBL] [Abstract][Full Text] [Related]
43. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
Moriyama T; Nishii R; Lin TN; Kihira K; Toyoda H; Jacob N; Kato M; Koh K; Inaba H; Manabe A; Schmiegelow K; Yang JJ; Hori H
Pharmacogenet Genomics; 2017 Jun; 27(6):236-239. PubMed ID: 28445187
[TBL] [Abstract][Full Text] [Related]
44. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease.
Van Dieren JM; Hansen BE; Kuipers EJ; Nieuwenhuis EE; Van der Woude CJ
Aliment Pharmacol Ther; 2007 Sep; 26(5):643-52. PubMed ID: 17697198
[TBL] [Abstract][Full Text] [Related]
45. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring.
Lim SZ; Chua EW
Front Pharmacol; 2018; 9():1107. PubMed ID: 30349479
[TBL] [Abstract][Full Text] [Related]
46. Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux JB; Peyrin-Biroulet L; Sparrow MP
Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
[TBL] [Abstract][Full Text] [Related]
47. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.
Zelinkova Z; Derijks LJ; Stokkers PC; Vogels EW; van Kampen AH; Curvers WL; Cohn D; van Deventer SJ; Hommes DW
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):44-9. PubMed ID: 16431304
[TBL] [Abstract][Full Text] [Related]
48. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
49. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
Lennard L; Cartwright CS; Wade R; Vora A
Br J Haematol; 2015 Apr; 169(2):228-40. PubMed ID: 25441457
[TBL] [Abstract][Full Text] [Related]
50. Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations.
Al-Mahayri ZN; Patrinos GP; Ali BR
Pharmacogenomics; 2017 May; 18(7):687-699. PubMed ID: 28468529
[TBL] [Abstract][Full Text] [Related]
51. Review article: thiopurines in inflammatory bowel disease.
Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
[TBL] [Abstract][Full Text] [Related]
52. [Frequency of serious adverse events of thiopurine treatment in normal thiopurine S-methyltransferase genotype children with inflammatory bowel disease].
Tárnok A
Orv Hetil; 2019 Feb; 160(5):179-185. PubMed ID: 30686035
[TBL] [Abstract][Full Text] [Related]
53. [Pharmacogenomics for leukemia treatment].
Tanaka Y
Rinsho Ketsueki; 2016 Jul; 57(7):910-8. PubMed ID: 27498738
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment.
Pavlovic S; Kotur N; Stankovic B; Zukic B; Gasic V; Dokmanovic L
Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30832275
[TBL] [Abstract][Full Text] [Related]
55. NUDT15: a novel player in thiopurine metabolism.
Meijer B; Mulder CJ; de Boer NK
J Gastrointestin Liver Dis; 2016 Jun; 25(2):261-2. PubMed ID: 27308664
[No Abstract] [Full Text] [Related]
56. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
[TBL] [Abstract][Full Text] [Related]
57. Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.
Yang JJ; Bhojwani D
Methods Mol Biol; 2013; 999():273-84. PubMed ID: 23666706
[TBL] [Abstract][Full Text] [Related]
58. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia.
Liang DC; Yang CP; Liu HC; Jaing TH; Chen SH; Hung IJ; Yeh TC; Lin TH; Lai CL; Lai CY; Shih LY
Pharmacogenomics J; 2016 Nov; 16(6):536-539. PubMed ID: 26503813
[TBL] [Abstract][Full Text] [Related]
59. [Usefulness of thiopurine methyltransferase polymorphism study and metabolites measurement for patients treated by azathioprine].
Guillotin V; Galli G; Viallard JF
Rev Med Interne; 2018 Jun; 39(6):421-426. PubMed ID: 29370945
[TBL] [Abstract][Full Text] [Related]
60. CRISPR/Cas9-Mediated Induction of Relapse-Specific
Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
